TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01613898

Intervention type: BIOLOGICAL
Intervention: Blood tests
Description: Blood tests
Study: NCT03161444

Intervention type: OTHER
Group type: OTHER
Intervention: Biological sample collection
Description: A blood sample collection for the study will be taken to each participant Each subject enrolled must have previously participated to the study CHIKVIH.
Study: NCT00126490

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01671878

Intervention type: OTHER
Group type: OTHER
Intervention: Reference Glucose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Food 1 (Cereal)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Food 2 (Biscuit)
Study: NCT02813577

Intervention type: DEVICE
Group type: OTHER
Intervention: Lutonix® 035 Drug Coated Balloon PTA Catheter
Description: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
Study: NCT04468152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary habits and intake
Description: Optical coherence tomography (OCT) withdrawals and central foveal thickness (CFT) evaluations of those included in the study were made by the doctor and directed to the dietician (researcher). The dietary intake of participants was assessed using a validated quantitative food frequency questionnaire (QFFQ) (21). The total food intake was then converted to total nutrient intake based on the food's nutrient profile. Standardized food recipes for Turkey and the Nutrition Information System (BEBIS) program, which is a food composition database for nutrient estimation, were used to determine the average daily energy and nutrient intake for each participant.
Study: NCT03727308

Intervention type: BEHAVIORAL
Intervention: Medical abortion pills sourced from pharmacies
Description: One cohort using medical abortion pills sourced from pharmacies

Intervention type: BEHAVIORAL
Intervention: Medical abortion pills sourced from health clinics
Description: One cohort using medical abortion pills sourced from health clinics
Study: NCT02390505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03646461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560mg PO daily (Imbruvica)
Description: BTK inhibitor combined with PD-1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560mg PO daily (Imbruvica)
Description: BTK inhibitor combined with PD-1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 400mg/m2 x 1 then 250 mg/m2 weekly 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3mg/kg biweekly 28 day cycle
Study: NCT04413006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Compassion for Chronic Pain Virtual Group Treatment Program
Description: 6-session group via video-conferencing for informational and experiential exercises to increase self-compassion in individuals with chronic pain
Study: NCT00888732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Aspart, BIAsp 70, BIAsp50, Human Insulin
Description: 0.2 U/IU/kg subcutaneous injection, single dose
Study: NCT06433492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-articular injection
Description: Three doses of intra-articular injection administered in weekely intervals.
Study: NCT03052426

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ergotron WorkFit - TL
Description: A sit to stand work station.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ergotron WorkFit - TL
Description: A sit to stand work station.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ergotron WorkFit - TL
Description: A sit to stand work station.
Study: NCT04036396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Enhanced Prevention Support
Description: Access to the newly developed GeoPassport App, incentives for accessing identified services, and a trained Peer Mentor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care plus Customized Referrals
Description: Participants in the control arm will continue to receive services they would normally receive consistent with the setting in which they were recruited. This includes substance use treatment in jail, substance use treatment at a residential recovery facility, and/or supportive housing services. The study will provide referrals customized to their needs and preferences.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care plus Customized Referrals
Description: Participants in the control arm will continue to receive services they would normally receive consistent with the setting in which they were recruited. This includes substance use treatment in jail, substance use treatment at a residential recovery facility, and/or supportive housing services. The study will provide referrals customized to their needs and preferences.
Study: NCT04472832

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Treatment A
Description: 6 tablets matched to mitapivat tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat 100 mg
Description: Two 50-mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat 100 mg
Description: Two 50-mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Treatment B
Description: 4 tablets matched to mitapivat tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat 300 mg
Description: Six 50-mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Treatment C
Description: 4 tablets matched to mitapivat tablet
Study: NCT04473677

Intervention type: DIAGNOSTIC_TEST
Intervention: The new qFIT and colonoscopy with pathological examination
Description: Detect hemoglobin in stool by the new qFIT before colonoscopy, detect colon lesion using colonoscopy and pathological examination.
Study: NCT02167139

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humira (adalimumab)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SB5 (proposed biosimilar to adalimumab)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB5 (proposed biosimilar to adalimumab)
Study: NCT02462915

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-gel
Description: a supraglottic airway devices without cuff and the material was Styrene Ethylene Butadiene Styrene.~gastric channel to the The gastric suction channel can facilitate venting and reduce the aspiration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endotracheal tube
Description: traditional and regularly use in many surgeries for maintaining the airway.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine, propofol, fentanyl and cisatracurium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine, propofol, fentanyl and cisatracurium
Study: NCT01567709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT01243580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho-Cyclen
Description: Ortho-Cyclen is an oral contraceptive containing 35 µg of EE and 250 µg of norgestimate (NGM) in a 21 - 7 day regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG200-15
Description: AG200-15 is a transdermal contraceptive delivery system delivering 100 - 120 mcg of LNG and 25 - 30 mcg EE
Study: NCT03112577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3500
Description: Intravenous (IV) use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3500
Description: Intravenous (IV) use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Subcutaneous (SC) use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Subcutaneous (SC) use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Inhalation use
Study: NCT02711709

Intervention type: OTHER
Intervention: Frailty Measurements
Description: A frailty index will be determined as a combination of factors.~An older adult is considered physically vulnerable when they experience:~1. muscle weakness~2. fatigue~3. low physical activity, and unintentional loss in body weight, which has been agreed upon by a consensus of experts.~This will be collected at baseline, 3, 6 and 12 months.

Intervention type: OTHER
Intervention: Modified Minnesota Leisure Time Activities
Description: A questionnaire used to assess physical activity will be administered at baseline, 3, 6 and 12 months.

Intervention type: OTHER
Intervention: Computed tomography morphometrics
Description: A CT scan will occur as standard of care while the patient is hospitalized. Two additional CT scans will occur at 3 and 12 months to assess for sarcopenia.

Intervention type: OTHER
Intervention: Mobility Monitors
Description: Mobility monitors will be placed on the patients during the duration of their hospital stay. They will then where them at 3, 6 and 12 months for up to 10 days.
Study: NCT03460262

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard cutiplast®
Description: Our standard dressing consists in a usual ready-to-use Smith and Nephew Cutiplast®. This dressing is open 48 hours after the operation (CDC recommendation) for the first time and then changed every day after wound disinfection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO®
Description: PICO® is a negative pressure wound therapy consisting in a 4 layers ready-to-use dressing connected to a small console, responsible for the aspiration. The system is canister free. The fluid drained from the wound is lost by evaporation for 80% of it and only 20% remains in the dressing. This permits to the dressing to be kept in place for maximum 7 days. The wound is not checked during the hospital stay, allowing the patient to leave the hospital earlier after the operation.
Study: NCT03089905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Experimental arm: end tidal concentration of 0.6 -0.8% or less. Active comparator arm: end tidal concentration of 2.5-3.0% or greater.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Experimental arm: end tidal concentration of 0.6 -0.8% or less. Active comparator arm: end tidal concentration of 2.5-3.0% or greater.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Experimental arm: loading dose: 1 mcg/kg, infusion starting at 0.1 mcg/kg/min or greater.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Experimental arm: loading dose:1mcg/kg, infusion: 1 mcg/kg/hr.
Study: NCT01814241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open label peanut OIT
Description: Subject will take increasing amounts of peanut protein up to a maximum maintenace dose of 1450mg.
Study: NCT03502356

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: In this group, patients will receive standard antibiotic prophylaxis CEFAZOLIN (at a dose of 1 g) and azithromycin (at a dose of 1g) 2 hours preoperative.
Study: NCT03241511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test
Description: Briefly, treatment sessions will include oral hygiene behavioral modification and scaling and root planning (removing the bacterial biofilm and calculus below the gum line) in order to eliminate etiologic factors and control periodontal inflammation. Once the treatment sessions are completed, the patients will enter the maintenance phase and will be followed for 6 months. In this phase, the patients will receive systematic supportive periodontal treatment (tooth cleanings above the gum line with re-enforcement of oral hygiene).
Study: NCT04145219

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sublingual allergy immunotherapy tablet
Description: For daily administration (1 tablet per day)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For daily administration (1 tablet per day)
Study: NCT02722499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Frequency Financial Incentive
Description: 1. Diabetes Education/Skills Component. Subjects will receive weekly telephone-delivered diabetes/skills training for 12 weeks with home telemonitoring.~2. High Frequency Financial Incentive: the high frequency incentive structure will receive a reward for uploading glucose measurements, attending educational sessions, and absolute percentage drops in HbA1c from baseline at 3-month follow-up, up to $300. Each week participants can receive up to $10 for uploading glucose measurements and having good glucose control throughout the week. If they upload measurements every day of the week and their average glucose measurements at the end of the week are 150 or below they will receive an additional $3. Participants can also earn $5 each week if they attend the educational session. After 3 months, if their HbA1c has dropped 2% from baseline, or absolute HbA1c is 7%, they will receive a reward of $130, for a 1% drop, or an absolute HbA1c between 7 and 8 they will receive a reward of $65.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Frequency Financial Incentive
Description: 1. Diabetes Education/Skills Component. Subjects will receive weekly telephone-delivered diabetes/skills training for 12 weeks with home telemonitoring.~2. Moderate Frequency Financial: the moderate frequency incentive structure will receive a reward for uploading glucose measurements, and absolute percentage drops in HbA1c from baseline at 3-month follow-up, up to $300. Each week participants can receive up to $10 for uploading glucose measurements and having good glucose control throughout the week. For each day they upload at least one glucose measurement, they will receive $1 (up to $7 at the end of the week). If they upload measurements every day of the week and their average glucose measurements at the end of the week are 150 or below they will receive an additional $3. After 3 months, if their HbA1c has dropped 2% from baseline, or absolute HbA1c is 7%, they will receive a reward of $170, for a 1% drop, or an absolute HbA1c between 7 and 8 they will receive a reward of $85

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Frequency Financial Incentive
Description: 1. Diabetes Education/Skills Component. Subjects will receive weekly telephone-delivered diabetes/skills training for 12 weeks with home telemonitoring.~2. Low Frequency Financial Incentive: the low frequency incentive structure will receive a reward for absolute percentage drops in HbA1c from baseline at 3-month follow-up, up to $300. After 3 months, if their HbA1c has dropped 2% from baseline, or absolute HbA1c is 7%, they will receive a reward of $300, for a 1% drop, or an absolute HbA1c between 7 and 8 they will receive a reward of $150.
Study: NCT04112212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescence molecular imaging procedure using vedolizumab-800CW
Description: First vedolizumab-800CW was administered intravenously. 2-4 days later a fluorescence molecular imaging procedure was performed to enable the visualization and detection of fluorescence signals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescence molecular imaging procedure using vedolizumab-800CW
Description: First vedolizumab-800CW was administered intravenously. 2-4 days later a fluorescence molecular imaging procedure was performed to enable the visualization and detection of fluorescence signals.

Intervention type: OTHER
Group type: OTHER
Intervention: Fluorescence molecular imaging procedure without prior administration of vedolizumab-800CW
Description: Fluorescence molecular imaging was performed to enable the visualization and detection of fluorescence signals.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fluorescence molecular imaging procedure using vedolizumab-800CW with prior administration of unlabeled vedolizumab
Description: Patients on vedolizumab therapy received vedolizumab-800CW iv or patients first received an unlabeled dose of vedolizumab prior to the iv administration of vedolizumab-800CW. 2-4 days later a fluorescence molecular imaging procedure was performed to enable the visualization and detection of fluorescence signals.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fluorescence molecular imaging procedure using vedolizumab-800CW with prior administration of unlabeled vedolizumab
Description: Patients on vedolizumab therapy received vedolizumab-800CW iv or patients first received an unlabeled dose of vedolizumab prior to the iv administration of vedolizumab-800CW. 2-4 days later a fluorescence molecular imaging procedure was performed to enable the visualization and detection of fluorescence signals.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fluorescence molecular imaging procedure using vedolizumab-800CW with prior administration of unlabeled vedolizumab
Description: Patients on vedolizumab therapy received vedolizumab-800CW iv or patients first received an unlabeled dose of vedolizumab prior to the iv administration of vedolizumab-800CW. 2-4 days later a fluorescence molecular imaging procedure was performed to enable the visualization and detection of fluorescence signals.
Study: NCT02472067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychologically - Based Physical Therapy
Description: Psychologically - Based Physical Therapy targeting risk factors for disability.
Study: NCT02424578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Capsules low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Capsules high dose
Study: NCT04193644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and Self-Compassion focussed exercises during walking training
Description: Mindfulness and Self-Compassion focussed exercises during walking training with moderate intensity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking training
Description: Walking training with moderate intensity
Study: NCT05343728

Intervention type: DIAGNOSTIC_TEST
Intervention: Thromboelastography
Description: Thromboelastography was done by using TEG 5000 Hemostasis Analyzer (Haemonetics Corp., USA)

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard coagulation profile laboratory examination
Description: Standard coagulation profile laboratory examination (platelets, PT/APTT, fibrinogen, and D-dimer) was performed by using Sysmex® CS-2500 and 5100 (Sysmex Corp., Japan)

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard coagulation profile laboratory examination
Description: Standard coagulation profile laboratory examination (platelets, PT/APTT, fibrinogen, and D-dimer) was performed by using Sysmex® CS-2500 and 5100 (Sysmex Corp., Japan)
Study: NCT03869008

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: gammaCore Sapphire
Description: gammaCore SapphireTM (non-invasive vagus nerve stimulator) is intended to provide non-invasive vagus nerve stimulation (nVNS) on the side of the neck. gammaCore provides a mild electrical stimulation to the vagus nerve, which runs through the neck and carries information to the central nervous system.~Subjects will be instructed to use the gammaCore Sapphire to stimulate 2 minutes on each side of the neck, twice a day, every day. The subject controls the intensity level of the electrical stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gammaCore Sapphire
Description: gammaCore SapphireTM (non-invasive vagus nerve stimulator) is intended to provide non-invasive vagus nerve stimulation (nVNS) on the side of the neck. gammaCore provides a mild electrical stimulation to the vagus nerve, which runs through the neck and carries information to the central nervous system.~Subjects will be instructed to use the gammaCore Sapphire to stimulate 2 minutes on each side of the neck, twice a day, every day. The subject controls the intensity level of the electrical stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: The Sham device delivers no electrical stimulations but subjects randomized to the Sham device will received the same instructions to use the Sham device to stimulate 2 minutes on each side of the neck, twice a day, every day for the first 4 weeks after randomization.
Study: NCT03937999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezlotoxumab
Description: Injection: 1,000 mg/40 mL (25 mg/mL) solution in a single-dose vial.
Study: NCT00324259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Study: NCT00351429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyglycolic acid suture
Description: PGA suture used in Trabeculectomy surgery
Study: NCT03665727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: The 15 minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experience in a non-judgmental fashion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Suggestion
Description: The 15 minute suggestion session is a scripted suggestion exercise that incorporates imagery and suggestions for changes in cognition, emotion, and body sensations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: The 15 minute psychoeducation session is a supportive session in which behavioral coping strategies for pain management are discussed.
Study: NCT01463085

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low-fat dairy
Description: Dietary Intervention of 3 servings per day of low-fat dairy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-fat dairy
Description: Dietary Intervention of 3 servings per day of low-fat dairy
Study: NCT03854877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health behaviour intervention
Description: The intervention uses the principles of acceptance-commitment therapy (ACT). It aims to increase healthy eating and good sleep. Based on personal needs participants can choose task for physical activity, relaxation, healthy eating, sleep eg. Their get regular feedback and support from their personal trainer via phone and computer.
Study: NCT03048006

Intervention type: PROCEDURE
Intervention: MRI with Dotarem
Study: NCT02618070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogurt

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogurt